日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial

CPX-351 与柔红霉素、阿糖胞苷和吉妥珠单抗治疗老年非不良风险 AML 患者的疗效比较:NCRI AML18 试验

Knapper, Steven; Dillon, Laura W; Babu, Malavika; Thomas, Abin; Thomas, Ian; Hourigan, Christopher S; Andrew, Georgia; Dillon, Richard; Gilkes, Amanda; Marquez Almuina, Nuria; King, Sophie; McCarthy, Nicholas; Bahr, Reem; Al-Ali, Rasha W; Stone, Louisa; Coats, Tom; Byrne, Jennifer; Green, Simone; Overgaard, Ulrik Malthe; Sellar, Rob S; Dennis, Mike; Mehta, Priyanka; Hills, Robert; Freeman, Sylvie D; Russell, Nigel H

Correction: Kingshott et al. Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer. Cancers 2021, 13, 825

更正:Kingshott 等人,《代谢状况的改变影响前列腺癌中 IGF-II/H19 印迹状态的调控》,Cancers 2021, 13, 825

Kingshott, Georgina; Biernacka, Kalina; Sewell, Alex; Gwiti, Paida; Barker, Rachel; Zielinska, Hanna; Gilkes, Amanda; McCarthy, Kathryn; Martin, Richard M; Lane, J Athene; McGeagh, Lucy; Koupparis, Anthony; Rowe, Edward; Oxley, Jon; Holly, Jeff M P; Perks, Claire M

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial

根据老年 AML 患者的残余疾病状态,采用氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星,或克拉屈滨联合柔红霉素和阿糖胞苷强化治疗:来自 NCRI AML18 试验的结果

Russell, Nigel H; Thomas, Abin; Hills, Robert K; Thomas, Ian; Gilkes, Amanda; Almuina, Nuria Marquez; Burns, Sarah; Marsh, Lucy; Vyas, Paresh; Metzner, Marlen; McCarthy, Nicholas; Andrew, Georgia; Byrne, Jennifer; Sellar, Rob S; Kelly, Richard; Cahalin, Paul; Overgaard, Ulrik Malthe; Mehta, Priyanka; Dennis, Mike; Knapper, Steven; Freeman, Sylvie D

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 (mut) AML in MRD(neg) remission after intensive induction

一项对3项大型多中心试验的汇总分析证实,在强化诱导治疗后达到微小残留病灶阴性缓解的NPM1突变型急性髓系白血病患者具有生存优势。

Döhner, Konstanze; Döhner, Hartmut; Späth, Daniela; Kapp-Schwoerer, Silke; Gilkes, Amanda; Thomas, Ian; Johnson, Sean; Potter, Nicola; Bevan, Yana; Othman, Jad; Russell, Nigel H; Röllig, Christoph; Thiede, Christian; Bornhäuser, Martin; Oellerich, Thomas; Hood, Tressa; Elder, Jenna; Carvajal, Luis A; DiMartino, Jorge; Dillon, Richard

Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival

急性髓系白血病细胞高表达雄激素受体,但其存活并不依赖雄激素信号通路。

Miraki-Moud, Farideh; Ariza-McNaughton, Linda; KoKo, Thinzar; Othman, Jad; Stronge, Randal; de Bono, Johann; Russell, Nigel; Thomas, Ian; Gilkes, Amanda; Burnett, Alan; Santiago, Leandro Rodrigues; Cafferty, Fay; Taussig, Leo; Thornhill, Allan; O'Connor, Simon; Bonnet, Dominique; Taussig, David C

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States

多模态和数据驱动的髓系肿瘤评估可改进疾病状态下的分类

Lachowiez, Curtis A; Asimomitis, Georgios; Bernard, Elsa; Devlin, Sean M; Tazi, Yanis; Creignou, Maria; Germing, Ulrich; Gattermann, Norbert; Gilkes, Amanda; Thomas, Ian; Bullinger, Lars; Döhner, Konstanze; Malcovati, Luca; Othman, Jad; Dillon, Richard; Eisfeld, Ann-Kathrin; Nicolet, Deedra; Issa, Ghayas C; Daver, Naval; Kadia, Tapan M; DiNardo, Courtney D; Ravandi, Farhad; Garcia-Manero, Guillermo; Montalban-Bravo, Guillermo; Russell, Nigel; Cazzola, Mario; Döhner, Hartmut; Huntly, Brian J P; Hasserjian, Robert P; Hellström-Lindberg, Eva; Papaemmanuil, Elli; Loghavi, Sanam

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML

在FLT3突变型急性髓系白血病(AML)中,米哚妥林联合吉妥珠单抗奥佐米星治疗并进行诱导化疗的安全性和有效性研究

Russell, Nigel; Othman, Jad; Cumming, Oliver; Thomas, Abin; Tedjaseputra, Aditya; Potter, Nicola; Jovanovic, Jelena; Gilkes, Amanda; Batten, Leona; Canham, Joanna; Hinson, Emily; Runglall, Manohursingh; Aucken, Phoebe; Kottaridis, Panos; Cavenagh, Jamie; Arnold, Claire; Freeman, Sylvie; Dennis, Mike; Knapper, Steven; Dillon, Richard

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星联合吉妥珠单抗可改善年轻新诊断急性髓系白血病患者的无事件生存期,并改善携带NPM1和FLT3突变患者的总生存期。

Russell, Nigel H; Wilhelm-Benartzi, Charlotte; Othman, Jad; Dillon, Richard; Knapper, Steven; Batten, Leona M; Canham, Joanna; Hinson, Emily L; Betteridge, Sophie; Overgaard, Ulrik Malthe; Gilkes, Amanda; Potter, Nicola; Mehta, Priyanka; Kottaridis, Panagiotis; Cavenagh, Jamie; Hemmaway, Claire; Arnold, Claire; Freeman, Sylvie D; Dennis, Mike

Risk Stratification in Older Intensively Treated Patients With AML

老年急性髓系白血病患者接受强化治疗的风险分层

Versluis, Jurjen; Metzner, Marlen; Wang, Ariel; Gradowska, Patrycja; Thomas, Abin; Jakobsen, Niels Asger; Kennedy, Alison; Moore, Rachel; Boertjes, Emma; Vonk, Christian M; Kavelaars, Francois G; Rijken, Melissa; Gilkes, Amanda; Schwab, Claire; Beverloo, H Berna; Manz, Markus; Visser, Otto; Van Elssen, Catharina H M J; de Weerdt, Okke; Tick, Lidwine W; Biemond, Bart J; Vekemans, Marie-Christiane; Freeman, Sylvie D; Harrison, Christine J; Cook, Jonathan A; Dennis, Mike; Knapper, Steven; Thomas, Ian; Craddock, Charles; Ossenkoppele, Gert J; Löwenberg, Bob; Russell, Nigel; Valk, Peter J M; Vyas, Paresh

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

吉妥珠单抗奥佐米星分次给药与单次给药治疗老年急性髓系白血病患者的获益决定因素:英国国家癌症研究所 (NCRI) AML18 试验

Freeman, Sylvie D; Thomas, Abin; Thomas, Ian; Hills, Robert K; Vyas, Paresh; Gilkes, Amanda; Metzner, Marlen; Jakobsen, Niels Asger; Kennedy, Alison; Moore, Rachel; Almuina, Nuria Marquez; Burns, Sarah; King, Sophie; Andrew, Georgia; Gallagher, Kathleen M E; Sellar, Rob S; Cahalin, Paul; Weber, Duruta; Dennis, Mike; Mehta, Priyanka; Knapper, Steven; Russell, Nigel H